Market Overview

UPDATE: Credit Suisse Upgrades St. Jude Medical to Outperform on Durata Outlook

Related STJ
UPDATE: St. Jude Medical Resolves FDA Warning
Markets Up As Russia Seeks To End Military Activity Near Ukraine

Credit Suisse upgraded St. Jude Medical (NYSE: STJ) from Neutral to Outperform and raised the price target from $43.00 to $48.00.

Credit Suisse noted, "Since Riata (STJ's recalled defib lead) failure reports began to circulate widely in 8/10, concerns about Durata's reliability (STJ's current defib lead) have weighed on STJ's valuation. While Durata concerns are likely to persist near-term, we came away from STJ's investor day impressed by the company's confidence in Durata and its optimism about the May HRS conference where STJ expects to see multiple favorable Durata studies."

St. Jude Medical closed at $41.17 on Friday.

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (STJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters